Typewriter Therapeutics discloses $56.3 million equity offering in Form D filing
The Cambridge, Massachusetts biotech reported selling the full amount of a private securities offering to six investors, according to an SEC filing.
Typewriter Therapeutics, Inc. filed a Form D with the Securities and Exchange Commission disclosing an equity offering. The filing lists a total offering amount of $56,299,999, with the total amount sold matching that figure and $0 remaining to be sold.1
The company reported a total of six investors who have already invested in the offering.1 The filing states the date of first sale as January 8, 2026,1 and it was submitted as a new notice rather than an amendment.1
Typewriter Therapeutics is a Delaware corporation, incorporated within the last five years, in 2022.1 The company lists its principal place of business as 238 Main Street, Office 2162, Cambridge, Massachusetts, 02142.1 It operates in the biotechnology segment of the health care industry group.1
The filing names Matthew Stanton as an executive officer and director, along with Kenneth Horne, Laura Tadvalkar, and Mikael Dolston as directors.1
The offering was made under Rule 506(b) of Regulation D.1 The company indicated it does not intend the offering to last more than one year.1 It also stated the offering is not being made in connection with a business combination transaction such as a merger, acquisition, or exchange offer.1
According to the filing, the minimum investment accepted from any outside investor was $0,1 and the company reported no sales commissions or finders' fees expenses.1 The notice was signed by Matthew Stanton, CEO, on September 11, 2026.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.